Mind Cure was formed as a response to a world suffering from mental health crisis and in urgent need of effective treatments. Mind Cure is interested in exploring related and diverse therapeutic areas beyond psychiatry, including neuropathic pain, neurodegenerative disease, and mental health.
Mind Cure anticipates in the future it may pursue or acquire technology and products, that are complimentary or related to its mission to identify, develop and commercialize products that enhance mental health and wellness, ease suffering and increase productivity.
Mind Cure seeks to identify and commercialize the therapeutic potential of nootropics, psychoactive products, and psychedelic substances that promote productivity and enhancing mental health.
Evaluating potential research programs, protocols and supportive infrastructure to drive clinical research.
Mind Cure Is evaluating the legal and commercial viability of the use of psychedelic compounds such as psilocybin as part of its future product candidates.
This sphere calls for Mind Cure to evaluate a path to the manufacture, import and supply of traditional and novel candidate active pharmaceutical agents for North American supply.
Taken together the 5 Spheres of Mind Cure’s interest in research, discovery, clinical programs, technology, and GMP scale up will be used in identifying our areas of interests; these areas may include psychedelic-assisted psychotherapy, regenerative medicine and neuroscience. Mind Cure’s foundational interests in the adaption of psychoactive substances. Beyond the mind and the symptoms of the body, Mind Cure is determined to transform the ideas of today into the products of tomorrow that unify mind-body connections of a world suffering from mental health crisis.
Mind Cure is investigating technology applications that could focuses on the connection between clinical patient‐trials that monitor, collect or use patient information in order to monitor the correlation between diagnosis and treatment.
Currently, most patients being treated for mental health concerns do not receive any meaningful data before and after therapy sessions. Mind Cure is investigating technology that could enable the collection of data between sessions. This would equip clinicians with additional patient feedback that may provide data-driven research and insights needed to prove the efficacy of treatments therapy.”
The first line of products that Mind Cure intends to launch are three types of organic, mushroom nootropics. These products will be launched under our Moonbeam Brand. The three products will be distributed under the following product names: Moonbeam Mushrooms: Focus; Moonbeam Mushrooms: Energy; and Moonbeam Mushrooms: Immunity. Each of these three products will be available in both powdered and capsule form
Mind Cure intends to evaluate the potential of developing proprietary research programs, protocols, and support infrastructure for conducting clinical research that would benefit mental health and wellness. Mind Cure is interested the potential of mental health clinical trial protocols that may include psychoactive and psychedelic based substances and investigate the ability to conduct clinical trials under the supervision and guidance of Health Canada.
This Product discovery sphere will look to investigate the potential of new discoveries and explore the therapeutic pathology and regenerative benefits of novel and traditional psychoactive chemical compounds that could be evaluated further in clinical studies. This investigation may include new and improved psychedelic-inspired product candidates ranging from proprietary new-psychedelic compounds to non‐psychedelic analogs with medicinal properties.
The entire process would be compliant with all regulatory certifications and licensing within all regulatory certifications and licensing within the Canadian federal regulatory agencies including Health Canada and the US Federal regulatory agencies including the FDA.
The importation of traditional and novel psychoactive substances into North America could be used to service clinical research programs, and satisfy an underserviced access to psychoactive active pharmaceutical ingredients (API) for research.
Sign up to download our corporate presentation and receive updates.